

VGI Health Technology Limited

Sydney New South Wales, 3 June 2022 – in accordance with section 251AA of the Corporations Act 2001 (Cth), the directors of VGI Health Technology Limited (the **Company** or **VTL**) advise that the shareholders of the Company passed all four resolutions in the Notice of Meeting dated 2 May 2022.

The resolutions were carried by way of a poll. Details of the resolutions and the proxies received in respect of each resolution are set out in the attached summary.

This announcement was authorised for release by the board of VGI Health Technology Limited.

For more information please contact:

Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed biotechnology company (NSX:VTL) developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

For more information see: <https://www.vgiht.com>

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant:
https://www.nsx.com.au/broker_list_print.asp

Results of Meeting

Resolution Details	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
	For	Against	Discretion	Abstain	For	Against	Abstain	Carried/not carried
1. Approval of the Disposal of a Substantial Asset to a Related Party of the Company (Invictus Biopharma Holdings Ltd)	31,207,673	27,888	109,540	294	31,317,213	27,888	294	Carried
2. Approval of the provision of a financial benefit to a related party of the Company (Dr Glenn Tong)	31,207,265	28,369	109,540	221	31,316,805	28,369	221	Carried
3. Approval of the provision of a financial benefit to a related party of the Company (Richard Estalella)	31,207,265	28,365	109,544	221	31,316,809	28,365	221	Carried
4. Approval of the provision of a financial benefit to a related party of the Company (David Kingston)	31,207,265	28,365	109,544	221	31,316,809	28,365	221	Carried